Actual versus projected cost avoidance for clinical pharmacy specialist-initiated medication conversions in a primary care setting in an integrated health system

Journal of Managed Care Pharmacy

Volumn 14, Issue 2, 2008, Pages 155-163

  Kroner, Beverly A ^a,b   Billups, Sarah J ^a,b   Garrison, Kathleen M ^a,b   Lyman, Alfred E ^a,b   Delate, Thomas ^a,b  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMLODIPINE; CITALOPRAM; FLUOXETINE; GABAPENTIN; GEMFIBROZIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; SIMVASTATIN; TERAZOSIN; VENLAFAXINE;

ADULT; AGE DISTRIBUTION; ALTERNATIVE MEDICINE; ARTICLE; CHRONIC DISEASE; CHRONIC PAIN; CLINICAL PHARMACY; COMPARATIVE STUDY; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; DATA BASE; DEPRESSION; DRUG COST; DRUG INFORMATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMERGENCY CARE; FEMALE; HEALTH CARE PLANNING; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTEGRATED HEALTH CARE SYSTEM; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICAL SPECIALIST; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; SCORING SYSTEM; VALIDATION PROCESS;

EID: 41349114871     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2008.14.2.155     Document Type: Article

References (27)

1. Landry FJ, Horwhat D, Tomich D, Pinski L. Felodipine as an alternative to more expensive calcium antagonists in mild to moderate hypertension. South Med J. 1996;89:573-77.
2. Billups SJ, Plushner SL, Olson KL, Koehler TJ, Kerzee J. Clinical and economic outcomes of conversion of simvastatin to lovastatin in a group-model health maintenance organization. J Manag Care Pharm. 2005;11(8):681-86. Available at: www.amcp.org/data/jmcp/ Formulary%20Management%20681-686.pdf.
3. Fugit RV, Resch ND. Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic. Am J Health Syst Pharm. 2000;57:1703-08.
4. Taylor AJ, Grace K, Swiecki J, et al. Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program. Pharmacotherapy. 2001;21:1130-39.
5. Grace KA, Swiecki J, Hyatt R, et al. Implementation of a therapeutic-interchange clinic for HMG-CoA reductase inhibitors. Am J Health Syst Pharm. 2002;59:1077-82.
6. Patel R, Lyman Jr. A, Clark DR, Hartman TJ, Chester EA, Kicklighter CE. Personal digital assistants for documenting primary care clinical pharmacy services in a health maintenance organization. Am J Health Syst Pharm. 2006; 63:258-61.
7. Patel RJ, Gray DR, Pierce R, Jafari M. Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs Medical Center. Am J Manag Care. 1999;5:465-74.
8. Ito MK, Lin JC, Morreale AP, et al. Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol. Am J Health Syst Pharm. 2001;58:1734-39.
9. Manzo BA, Matalka MS, Ravnan SL. Evaluation of a therapeutic conversion from amlodipine to felodipine. Pharmacotherapy. 2003;23:1508-12.
10. Alexis G, Henault R, Sparr HB. Conversion from glipizide to glyburide: long-term follow-up of a cost-impact survey focusing on the elderly. Clin Ther. 1993;15:607-15.
11. Tran F, Boggie DT, Delattre ML, Schaefer MG, Morreale AP, Plowman BK. Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib. Am J Health Syst Pharm. 2004;61:1391-94.
12. Lee AJ, Boro MS, Knapp KK, Meier JL, Korman NE. Clinical and economic outcomes of pharmacist recommendations in a Veterans Affairs medical center. Am J Health Syst Pharm. 2002;59:2070-77.
13. Clay DR, Bourg MP, Lawrence DB. Outcomes of an amlodipine-to-felodipine therapeutic interchange program. Am J Health Syst Pharm. 2000; 57:1604-07.
14. Hilleman DE, Reyes AP, Wurdeman RL, Faulkner M. Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension. J Hum Hypertens. 2001;15:559-65.
15. Baluch WM, Gardner JS, Krauss RH, Scholes D. Therapeutic interchange of conjugated and esterified estrogens in a managed care organization. Am J Health Syst Pharm. 1999;56:537-42.
16. Gardner J, Scholes D, Baluch W, Krauss R. Acceptability of a substitution of estrogen replacement therapy to women enrolled in a health maintenance organization. J Womens Health. 1998;7:1027-31.
17. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.
18. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.
19. Amidon PB, Jankovich R, Stoukides CA, Kaul AF. Proton pump inhibitor therapy: preliminary results of a therapeutic interchange program. Am J Manag Care. 2000;6:593-601.
20. Condra LJ, Morreale AP, Stolley, Marcus D. Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. Am J Managed Care. 1999;5:631-38.
21. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-61.
22. Stebbins MR, Kaufman DJ, Lipton HL. The PRICE clinic for low-income elderly: a managed care model for implementing pharmacist-directed services. J Manag Care Pharm. 2005:11:333-41. Available at: www.amcp.org/data/jmcp/contemporary_333_341.pdf.
23. McMullin ST, Hennenfent JA, Ritchie DJ, et al. A prospective, randomized trial to assess the cost impact of pharmacist-initiated interventions. Arch Intern Med. 1999;159:2306-09.
24. Savani N, Martin A, Browning D. Switching patients with migraine from sumatriptan to other triptans increases primary care costs. Clin Pract. 2004; 58:758-63.
25. Meissner B, Dickson M, Shinogle J, Reeder CE, Belazi D, Senevirante V. Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization. J Manag Care Pharm. 2006;12:331-40. Available at: www.amcp.org/data/jmcp/formulary_management_331-340.pdf.
26. Delate T, Fairman K, Carey S, Motheral B. Randomized controlled trial of a dose consolidation program. J Manag Care Pharm. 2004;10:396-403. Available at: www.amcp.org/data/jmcp/Research-396-403.pdf.
27. Gershovich OE, Billups SJ, Delate T, Kicklighter Hoffman C, Carroll N. Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches. J Manag Care Pharm. 2006:12:246-53. Available at: www.amcp.org/data/jmcp/Formulary%20Management_246-253.pdf.